Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Other Non Operating Income: 2018-2024

Historic Other Non Operating Income for Allogene Therapeutics (ALLO) over the last 7 years, with Dec 2024 value amounting to -$3.9 million.

  • Allogene Therapeutics' Other Non Operating Income rose 92.79% to -$81,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 million, marking a year-over-year increase of 77.71%. This contributed to the annual value of -$3.9 million for FY2024, which is 78.02% up from last year.
  • Allogene Therapeutics' Other Non Operating Income amounted to -$3.9 million in FY2024, which was up 78.02% from -$17.8 million recorded in FY2023.
  • Allogene Therapeutics' Other Non Operating Income's 5-year high stood at -$3.6 million during FY2021, with a 5-year trough of -$67.3 million in FY2020.
  • Over the past 3 years, Allogene Therapeutics' median Other Non Operating Income value was -$9.4 million (recorded in 2022), while the average stood at -$10.4 million.
  • Per our database at Business Quant, Allogene Therapeutics' Other Non Operating Income crashed by 487.89% in 2020 and then soared by 94.69% in 2021.
  • Over the past 5 years, Allogene Therapeutics' Other Non Operating Income (Yearly) stood at -$67.3 million in 2020, then surged by 94.69% to -$3.6 million in 2021, then tumbled by 164.32% to -$9.4 million in 2022, then slumped by 88.85% to -$17.8 million in 2023, then spiked by 78.02% to -$3.9 million in 2024.